HomeAI · summaries
Storia in 2 fonti
GSK ends brain drug alliance with Alector
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
GSK ends brain drug alliance with Alector
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
- ·
endpoints.news
GSK walks away from Alector pact as immuno-neurology bet fizzles
GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline preclinical-only.